Bicalutamide in Treating Patients With Metastatic Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 120
Updated:4/6/2019
Start Date:March 2007
End Date:March 2020

Use our guide to learn which trials are right for you!

Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study

RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such
as bicalutamide, may stop the adrenal glands from making androgens.

PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients
with metastatic breast cancer.

OBJECTIVES:

Primary

- Determine the 6-month efficacy rate of bicalutamide as first-, second-, or third-line
therapy in patients with androgen receptor-positive and estrogen receptor- and
progesterone receptor-negative metastatic breast cancer.

Secondary

- Determine the 6-month progression-free survival of patients treated with this drug.

- Evaluate the safety of this drug in these patients.

- Evaluate changes in estradiol, total and free testosterone, and sex-hormone binding
globulin in response to androgen blockade in patients treated with this drug.

- Evaluate tissue, including cytokeratins 5/6 and 17, SPDEF, ALCAM, ERBB2, FGFR4, and
prostate-specific antigen (PSA), using immunohistochemical analysis in patients treated
with this drug.

OUTLINE: This is a open-label study.

Patients receive oral bicalutamide once daily for 4 weeks. Treatment repeats every 4 weeks
for 6 months in the absence of disease progression or unacceptable toxicity. Patients
achieving complete response, partial response, or stable disease may continue to receive
bicalutamide as above at the discretion of the investigator.

Patients undergo blood and tissue sample collection for correlative studies. Samples are
analyzed for hormonal levels, including estradiol, total testosterone, free testosterone, and
sex-hormone binding globulin, and proteins, including ALCAM, SPEDF, and CK 5/6, by
immunohistochemical analysis at baseline, after course 1, and at the end of the study.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

- Histologically confirmed adenocarcinoma of the breast

- Stage IV disease

- Measurable or non-measurable disease

- Patients with HER2/neu-positive disease must have received prior trastuzumab
(Herceptin®)

- No active brain metastases or leptomeningeal disease

- History of brain metastases allowed provided lesions are stable for at least 3
months as documented by head CT scan or MRI of the brain

- Hormone receptor status:

- Estrogen receptor- and progesterone receptor-negative*

- Androgen receptor-positive* NOTE: *Samples are considered positive if greater
than 10% of cell nuclei are immunoreactive

PATIENT CHARACTERISTICS:

- Male or female

- Menopausal status not specified

- ECOG performance status 0-1

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 9 g/dL

- AST and ALT ≤ 2.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastases are present in the
absence of liver metastases)

- Creatinine ≤ 1.5 mg/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No serious medical or psychiatric illness

- No serious active infection

- No other malignancy within the past 5 years except nonmelanoma skin cancer

- No hypersensitivity reaction to bicalutamide or any of the tablet's components

PRIOR CONCURRENT THERAPY:

- At least 2 weeks since prior cytotoxic chemotherapy and recovered

- At least 3 weeks since prior investigational drugs

- At least 4 weeks since prior major surgery and recovered

- Prior neoadjuvant or adjuvant chemotherapy allowed

- Any number of chemotherapy regimens are allowed for metastatic disease

- Prior hormonal therapy allowed

- No concurrent chemotherapy, other hormonal therapy, immunotherapy, or biological
therapy

- No concurrent trastuzumab (Herceptin®)

- No concurrent enrollment in another clinical trial in which investigational procedures
are performed or investigational therapies are administered
We found this trial at
8
sites
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Cancer Center The Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
1600 Divisadero Street
San Francisco, California 94115
888.689.8273
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
101 Manning Drive
Chapel Hill, North Carolina 27514
(919) 966-0000
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill One of the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
20 Duke Clinic Cir
Durham, North Carolina 27710
(888) 275-3853
Duke Cancer Institute Leading-edge cancer care and research have been a hallmark of Duke Medicine...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
3970 Reservoir Rd NW E501
Washington, District of Columbia 20007
(202) 687-2110
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Georgetown Lombardi Comprehensive Cancer Center, part...
?
mi
from
Washington,
Click here to add this to my saved trials